Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Chua

Pulmonary Disease Leominster, MA Medical Doctor

NPI 1659534501 CMS profile 496071

100 Hospital Rd, Suite 2A, Leominster, MA 01453

Open in the dashboard

General payments

$10,526

562 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Chua of Leominster, MA is reported in the CMS Open Payments database as having received $10,526 across 562 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,831 135
2024 General $1,922 87
2023 General $1,888 95
2022 General $1,199 64
2021 General $735 46
2020 General $611 45
2019 General $1,339 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Chua
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ryan Chua were reported at $2,831. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ryan Chua Pulmonary Disease median Middle half National median
2019 $1,339 $377 $109–$1,340 $163
2020 $611 $230 $56–$907 $114
2021 $735 $269 $68–$1,072 $132
2022 $1,199 $390 $100–$1,457 $149
2023 $1,888 $419 $114–$1,659 $160
2024 $1,922 $476 $123–$1,818 $164
2025 $2,831 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,735 111 payments
  2. GlaxoSmithKline, LLC. $2,649 196 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $706 35 payments
  4. Regeneron Healthcare Solutions, Inc. $569 36 payments
  5. Genzyme Corporation $552 37 payments
  6. Actelion Pharmaceuticals US, Inc. $369 14 payments
  7. Electromed, Inc. $251 16 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $189 8 payments
  9. United Therapeutics Corporation $186 8 payments
  10. Amgen Inc. $177 8 payments
  11. Other $2,143 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,352 558 payments
  2. Education $174 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,367 98 payments
  2. FASENRA $1,147 41 payments
  3. NUCALA $900 54 payments
  4. AIRSUPRA $737 24 payments
  5. DUPIXENT Immunology $629 36 payments
  6. BREZTRI $531 19 payments
  7. TEZSPIRE $413 13 payments
  8. SYMBICORT $405 14 payments
  9. DUPIXENT Inflammation And Immunology $363 22 payments
  10. OFEV $360 18 payments
  11. Other $5,180 272 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,615

Median for Pulmonary Disease: 936

Drug cost

$547,734

Median for Pulmonary Disease: $487,987

Branded share of claims

67.9%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 188 $172,725
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 92 $91,319
Breo Ellipta Fluticasone/Vilanterol Brand 94 $49,730
Nucala Mepolizumab Brand 11 $47,069
Spiriva Respimat Tiotropium Bromide Brand 44 $29,567
Symbicort Budesonide/Formoterol Fumarate Brand 74 $26,236
Eliquis Apixaban Brand 23 $18,910
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 33 $17,679
Advair Hfa Fluticasone Propion/Salmeterol Brand 25 $16,113
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 58 $13,355

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$268,149

Medicare's payments for the services billed

Medicare patients

1,111

Average age 72

Services billed

2,604

621 women, 490 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 53%
Arthritis 47%
Ischemic heart disease 45%
Depression 42%
Diabetes 38%
Chronic kidney disease 36%
Heart failure 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $386
$386 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $328
$328 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $155
  • SANOFI-AVENTIS U.S. LLC $57
$212 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $195
$195 188 —
NUCALA
  • GlaxoSmithKline, LLC. $139
$139 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

562 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record